Cancer Supportive Care Drugs Market (By Therapeutic Class: G-CSFs, Anti-emetics, ESAs, Bisphosphonates, Opioids, NSAIDs & Others)- Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.    COVID 19 Impact on Cancer Supportive Care Drugs Market

5.1.    COVID-19 Landscape: Cancer Supportive Care Drugs Industry Impact

5.2.    COVID 19 - Impact Assessment for the Industry

5.3.    COVID 19 Impact: Global Major Government Policy

5.4.  Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6.  Market Dynamics Analysis and Trends

6.1.  Market Dynamics

6.1.1.    Market Drivers

6.1.2.    Market Restraints

6.1.3.    Market Opportunities

6.2.  Porter’s Five Forces Analysis

6.2.1.    Bargaining power of suppliers

6.2.2.    Bargaining power of buyers

6.2.3.    Threat of substitute

6.2.4.    Threat of new entrants

6.2.5.    Degree of competition

Chapter 7.  Competitive Landscape

7.1.1.    Company Market Share/Positioning Analysis

7.1.2.    Key Strategies Adopted by Players

7.1.3.    Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8.  Global Cancer Supportive Care Drugs Market, By Therapeutic Class

8.1.  Cancer Supportive Care Drugs Market, by Therapeutic Class Type, 2020-2027

8.1.1.    G-CSFs (Granulocyte-colony Stimulating Factors)

8.1.1.1. Market Revenue and Forecast (2016-2027)

8.1.2.    ESAs (Erythropoiesis Stimulating Agents)

8.1.2.1. Market Revenue and Forecast (2016-2027)

8.1.3.    Anti-emetics

8.1.3.1. Market Revenue and Forecast (2016-2027)

8.1.4.    Bisphosphonates

8.1.4.1. Market Revenue and Forecast (2016-2027)

8.1.5.    Opioids

8.1.5.1. Market Revenue and Forecast (2016-2027)

8.1.6.    NSAIDs and others

8.1.6.1. Market Revenue and Forecast (2016-2027)

Chapter 9.  Global Cancer Supportive Care Drugs Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.1.2.    U.S.

9.1.3.    Rest of North America

9.1.3.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.2.2.    UK

9.2.2.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.2.3.    France

9.2.3.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.2.4.    Rest of Europe

9.2.4.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.3.2.    India

9.3.2.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.3.3.    China

9.3.3.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.3.4.    Japan

9.3.4.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.3.5.    Rest of APAC

9.3.5.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.4.2.    GCC

9.4.2.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.4.3.    North Africa

9.4.3.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.4.4.    South Africa

9.4.4.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.4.5.    Rest of MEA

9.4.5.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.5.2.    Brazil

9.5.2.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

9.5.3.    Rest of LATAM

9.5.3.1. Market Revenue and Forecast, by Therapeutic Class (2016-2027)

Chapter 10.  Company Profiles

10.1.  Amgen, Inc.

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.  Merck & Co., Inc.

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.  Johnson & Johnson Services, Inc.

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.  Heron Therapeutics, Inc.

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.  Novartis AG

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.  GlaxoSmithKline plc (GSK)

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.  F. Hoffmann-La Roche Ltd.

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.  Helsinn Healthcare SA

10.8.1.  Company Overview

10.8.2.  Product Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

Chapter 11.  Research Methodology

11.1.  Primary Research

11.2.  Secondary Research

11.3.  Assumptions

Chapter 12.  Appendix

12.1.  About Us

12.2.  Glossary of Terms